i&i Biotech Fund

Antiverse is an innovative antibody discovery company that aims to transform drug development by leveraging a unique platform combining structural biology, machine learning, and medicine. The company specializes in predicting antibody-antigen binding and generating antibody drug candidates for challenging targets. By utilizing advanced machine learning techniques and cell-free protein synthesis, Antiverse enables pharmaceutical companies and contract research organizations to accelerate the discovery of antibody hits, ultimately making the drug development process more efficient and cost-effective. Through its commitment to advancing medical science, Antiverse seeks to create meaningful breakthroughs that can significantly impact patient lives.

Captain T Cell is a start-up focused on the development of T cell-based immunotherapies for cancer patients. The company specializes in identifying novel high-efficiency T cell receptors (TCRs) to enhance the efficacy of its immunotherapy candidates. By concentrating on chemistry, manufacturing, and controls (CMC) as well as preclinical development, Captain T Cell aims to create innovative therapies specifically targeting solid tumors that are not adequately addressed by current treatment options. Its mission is to provide patients with new avenues for effectively combating their cancer diagnoses.

CasInvent Pharma is a biotechnology company focused on developing pharmaceutical solutions for the treatment of specific malignancies. It specializes in creating therapeutic compounds that utilize proprietary selective inhibitors of enzymes from the Casein Kinase 1 (CK1) family. These inhibitors target the mechanisms responsible for the migration of leukemia cells into lymphoid organs, thereby aiding in the treatment of leukemias, lymphomas, and solid tumors. Through its innovative approach, CasInvent Pharma aims to enhance treatment options for patients afflicted with these challenging diseases.

HeartBeat.bio is a privately funded drug discovery company dedicated to advancing the treatment of heart failure and cardiomyopathies. It has developed a high-throughput three-dimensional screening platform that utilizes self-organizing cardiac organoids. By generating induced pluripotent stem cell (iPSC)-derived, multi-cellular cardiac tissue models from both healthy donors and patients, the company creates systems that accurately mimic human heart physiology. This innovative approach aims to transform the cardiovascular drug discovery process, significantly improving success rates in clinical trials while minimizing the time and cost associated with compound development. HeartBeat.bio's work is poised to impact the future of cardiac healthcare through more effective drug development methodologies.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in the commercialization of advanced biosensor technology. The company focuses on developing photonic biosensors that integrate optical chips with waveguides to facilitate multiplexed biosensing. This technology enables real-time monitoring through highly sensitive refractive index sensors, allowing for label-free biosensing. Delta Diagnostics aims to provide rapid, sensitive, and cost-effective solutions that can significantly enhance research in the Life Sciences sector. By enabling accurate measurement of multiple biomarkers within minutes, the company aspires to drive new discoveries and foster the development of innovative diagnostics.

Sophomer is a company that specializes in developing synthetic polymers intended to replace bovine serum albumin in immunological tests. By integrating the fields of immunoassays and polymer chemistry, Sophomer offers innovative solutions for immunochemical assays, enhancing the accuracy and efficiency of these diagnostic tools. The company's focus on artificial polymers aims to improve the quality of testing while addressing the limitations associated with traditional protein-based reagents.

Enzyre is a developer of innovative diagnostic technology aimed at enhancing patient care through point-of-care solutions. The company specializes in ambulant diagnostic devices that facilitate blood coagulation testing, allowing patients to perform up to twelve different reactions using a small volume of blood. This technology is designed to empower patients to conduct tests in various settings, including at home, while traveling, or in critical care environments, all without the need for traditional laboratory infrastructure. By bringing laboratory capabilities directly to the patient, Enzyre seeks to improve quality of life while maintaining cost-effectiveness in healthcare.

Nanoligent is a biotech company that originated as a spin-off from Universitat Autònoma de Barcelona and Institut de Recerca de l'Hospital de la Santa Creu I Sant Pau. The company focuses on the design and development of targeted therapeutic biologics, particularly in the realm of nanotechnology-based anti-cancer treatments. Utilizing advanced protein engineering and nanobiotechnology, Nanoligent creates self-assembling protein nanoparticles that selectively target and kill metastatic cancer cells. This innovative approach aims to enhance treatment effectiveness while minimizing adverse effects, ultimately striving to improve patient outcomes by developing medicines that directly address the cells affected by disease.

CasInvent Pharma is a biotechnology company focused on developing pharmaceutical solutions for the treatment of specific malignancies. It specializes in creating therapeutic compounds that utilize proprietary selective inhibitors of enzymes from the Casein Kinase 1 (CK1) family. These inhibitors target the mechanisms responsible for the migration of leukemia cells into lymphoid organs, thereby aiding in the treatment of leukemias, lymphomas, and solid tumors. Through its innovative approach, CasInvent Pharma aims to enhance treatment options for patients afflicted with these challenging diseases.

Sampling Human is a biotechnology company that develops computational tools to measure and analyze complex single-cell and spatial omic data on an industrial scale. Their technology enables pre-symptomatic screening, personalized medicine, and drug discovery by translating vast amounts of genetic analysis data into practical applications in fields such as diagnostics and bioengineering.